On May 13, 2025 Stylus Medicine, Inc. ("Stylus"), a biotechnology company dedicated to developing transformative in vivo genetic medicines, reported presentations showcasing its genome engineering approach and in vivo CAR-T platform at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana (Press release, Stylus Medicine, MAY 13, 2025, View Source(asgct)-28th-annual-meeting-1 [SID1234653001]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"On the heels of our company launch and Series A financing, the Stylus team is honored to present our work to the scientific community at this year’s ASGCT (Free ASGCT Whitepaper) Annual Meeting, highlighting our advances in recombinase engineering and demonstrating the therapeutic potential of our targeted LNP/recombinase-based in vivo CAR-Ts," said Jason Fontenot, Ph.D., Chief Scientific Officer of Stylus Medicine. "At Stylus, we are committed to realizing the revolutionary potential of genetic medicines. We are taking a focused "medicines first" approach to build a potent, flexible, and scalable in vivo platform, with the goal of bringing the curative promise of CAR-T therapies to all patients in need."
ASGCT Annual Meeting Presentation Details:
Oral Presentation:
Title: Engineering High-Efficiency, High-Specificity Recombinases for Therapeutic In Vivo Genome Engineering
Session: Novel Approaches to Gene Targeting and Gene Correction
Presenter: Christopher J. Wilson, Ph.D., Senior Vice President, Genome Engineering
Date, Time and Location: Thursday, May 15, 2025, 1:30 PM – 3:15 PM CT, New Orleans Theater B
Abstract: 188
Summary: Stylus will present the development of therapeutic-grade recombinases for in vivo genetic medicines. The company reports engineering high-efficiency, high-specificity recombinases targeted to a novel safe harbor site in the human genome. The company’s engineered recombinases act without the use of landing pads, protein fusions, or guide RNAs and possess a well-defined integration profile. These proprietary recombinases serve as the foundation of Stylus’ powerful and elegant off-the-shelf, in vivo genetic medicines platform, which features single-step insertion of multi-kb therapeutic payloads.
Poster Presentation:
Title: Efficient and Effective In Vivo CAR-T Generation Using Recombinase-Based, Precise, High-Capacity, Off-the-Shelf, LNP-Based In Vivo Genomic Engineering
Presenter: Celeste Richardson, Ph.D., Senior Vice President, Immunology
Date and Time: Tuesday, May 13, 2025, 6:00 PM – 7:30 PM CT
Abstract: 797
Summary: Stylus will present advances from its powerful and elegant in vivo CAR-T platform, which combines a proprietary recombinase that enables sequence-specific genome integration with cell-targeted lipid nanoparticle (LNP) delivery. Using a humanized NSG mouse tumor model, a single dose of the company’s off-the-shelf in vivo CAR-T therapy demonstrated rapid and sustained tumor regression. By combining engineered recombinases with targeted LNP delivery, Stylus has created a platform to enable flexible and scalable in vivo CAR-T therapies, overcoming major limitations of ex vivo cell therapy.